This paper analyzes the routine failures and operating flow of full-functional DR-EIDOS3000 and points out the design deficiencies of the detector stand,the elevating table and the console.At last,some countermeasures are suggested for the hidden trouble.

AIM: To prepare the asperosaponin—phospholipid compound to improve the bioavailability of asperosaponin in rat intestine in situ. METHODS: Ratio of asperosaponin to phospholipid was chosen as index to screen the optimal proportion based on the orthogonal design.Rat intestine perfusion was use to compare aspersaponin absorption under with and without phospholipid. RESULTS: Asperosaponin—phospholipid compound showed the markedly improvement in absorption capacity and absorption rate. CONCLUSION: The experiment recommends that asperosaponin in the combination with phospholipid is better than only used asperosaponin concerning bioavailability.

Objective To Screen out incidence of vitamin K deficiecy and complicated with hemorrhage in newborn patients, infant patients and normal neonates, and also study on the treatment of vitamin K deficiency. Methods Using emzymoimmunoelectrophoresis to test PIVKA Ⅱ in umbilical and vein blood. Results The incidence of vitamin K deficiency in normal neonates, newborn patients (≤ 5 days) and infants patients (25~60 days) are 31.2%,47.6% and 31.8%. The incidence of hemorrhage in newborn patients (≤5 days) is 26.0%, infant patients (25~60 days) is 66.6%. Intramuscular injection of vitamin K 1 1 mg is the proper dosage to prevent and treat vitamin K deficiency. Conclusion The neonates right after birth or about 25 days after birth, especially those of breast feeding and who are getting lievr and gall diseases should receive vitamin K 1 to prevent vitamin K deficiency.

Radioactive Protective aprons are used to reduce radiation dose during fluoroscopy and exposure.Tears,cracks and holes can be detected by X-ray inspection.By establishing the rejection criteria,routine inspection and renew,the radioactive safety can be acheieved.

Twenty-seven patients with subclinical hyperthyroidism(SH)complicated by paroxysmal atrial fibrillation(PAF)were treated with methimazole plus bisoprolol.All patients were examined by Doppler echocardiogram and 24 h ambulatory electrocardiograms before and 3 months after treatment.Serum FT3,FT4,and TSH levels were measured with RIA.The results showed that low-dose methimazole therapy could improve the left ventricular diastolic function(P < 0.01)and help maintain sinus rhythm.The incidence of subclinical hypothyroidism was low.Low-dose methimazole was effective and safe in patients with SH complicated by PAF.

1. The blood supply of the tensor fascia lata myocutaneous free flap comes chiefly from the ascending branch of the lateral circumflex artery (76.74％) or its ascending and the transverse branches (23.26％). In most cases the ascending branch may be served as the vascular pedicle of myocutaneous free flap in transplatation. In a few cases the transverse branch my be used instead of the ascending one.2. The projection of the origin of the lateral circumflx artery on the body surface is at a point averaging 96.5mm below, and 49.2mm medial to the anterior superior iliac spine. This point is the surface landmark of the lateral circumflex artery. 3. The branches of the lateral circumflex artery may be classified into four types. Type 1—32 cases, 74.42％; Type Ⅱ—3 cases, 6.98％; Type Ⅲ—7 cases, 16.28％; Type Ⅳ—1 cases, 2.33％.4. The tensor fascia lata is chiefly supplied by the ascending branch of the lateral circumflex artery, it divides into a short superior and a long inferior twigs. Both twigs enter the muscle and form abundant anastomoses in the subcutaneus tissues. In order to reduce the thick ness of the free flap for the use in plastics, the superior twig with its supplying muscle is cut away and the inferior one's left to supply myocutaneus flap.5. The angle between the ascending branch and the inner surface of the tensor fasca lata varies between 44? to 120?, with an average of 66.5?. The original angle must be kept in transplantation, which favours the survival of the myocutaneus free flap.

Objective To investigate the differences of clinical efficacy and untoward reaction of different chemotherapy regi‐mens for patients with malignant glioma on different expression levels of O6‐methylguanine‐DNA‐methyltransferase(MGMT) ,in order to provide references for clinical treatment .Methods Totally 90 cases of patients with malignant glioma in our hospital from January 2011 to January 2013 were selected ,among them ,64 cases of MGMT negative expressing patients were divided into group A and group B with 32 cases in each group ,and 26 cases of MGMT positive expressing patients were enrolled into the group C . Group A was treated with combination of radiotherapy ,teniposide and nimustine ,group B was treated with radiotherapy‐temozolo‐mide combination regimen ,group C was treated with combination of radiotherapy ,teniposide and nimustine .The untoward reactions of the three groups were compared ,and the survival rate was observed after one year follow‐up .Results The hemoglobin ,leuko‐cyte ,granulocyte ,platelet ,bleeding ,alanine aminotransferase ,creatinine ,urea nitrogen ,peripheral neuritis ,untoward reactions a‐mong the three groups had no statistically significant differences (P>0 .05);the incidence rates of nausea and vomiting ,diarrhea , constipation among the three groups had statistically significant differences(P<0 .05) ,in which group C was significantly higher than that of group A and group B(P<0 .05) .Only one case in the group C was lost in the one year follow‐up .The median survival time was 10 months in group A and group B ,and was 7 months in group C .The median survival time in group C was significantly lower when compared with that in group A and group B(χ2 =7 .673 ,P=0 .006 ;χ2 =6 .395 ,P=0 .011) ,while there was no signifi‐cant difference of median survival time between group A and group B(χ2 =0 .063 .P=0 .802) .Conclusion The long‐term prognosis of patients with negative MGMT expression might be significantly worse than that of patients with negative MGMT expression in glioma .

Objective: To observe the effect of ivabradine (IVA) on atrial and ventricular monophasic action potential duration (MAPD) and its proarrhythmic action at presence of sea anemone toxin-II (ATX-II) in isolated rabbit heart modelin vitro. Methods: The perfusion of isolated heart from female New Zealand white rabbit was conducted by Langendorff method in vitro. Left atrial and left ventricular endo- , epi-cardial action potential were recorded when pacing with ifxed frequency of 350 ms (in correspondence with the heart rate of 171 times/min) to observe the effect of IVA alone and ATX-II (3 nmol/L) with IVA on MAPD90. In addition, to observe the action of IVA alone and ATX-II with IVA on proarrhythmia when IVA reducing the heart rate to autonomous cardiac rhythm as (156±10) times/min. Results: IVA at (3-10) μmol/L prolonged atrial and ventricular endo- , epi-cardial MAPD90 by (15.9 ± 2.0) ms, (31.5 ± 4.0) ms and (23.9 ± 3.0) ms (n=6,P<0.01), respectively. ATX-II at 3 nmol/L prolonged atrial and ventricular MAPD90 by (36.5 ± 5.0)ms and (19.9 ± 3.0) ms, (19.5 ± 4.0) ms (n=6,P<0.01) respectively. With ATX-II treatment, IVA at (6-10) μmol/L decreased atrial MAPD90 by (14.4 ± 4.0) ms (n=6,P<0.01), it induced atrial arrhythmia. With 3 nmol/L of ATX-II treated ventricle, IVA at (3-10) μmol/L obviously prolonged endo- and epi-cardial MAPD90 by (36.2 ± 7.0) ms and (27.5 ± 5.0) ms(n=6,P<0.01), respectively. IVA didn’t increase ventricular beat-to-beat variability and transmural dispersion of MAPD90 no matter with or without ATX-II treatment, no ventricular arrhythmia occurred. Conclusion: IVA prolongs both atrial and ventricular MAPD, with increased late sodium current, IVA may induce atrial arrhythmia but not ventricular arrhythmia in experimental rabbits in vitro.

OBJECTIVE To explore the safe and effective dose of sirolimus (Rapamycin,Sir) and its effect on seizure comorbidities. METHODS Immature C57BL/6 mice at postnatal 10 d of age were administered with kainic acid(KA) 12.0 mg · kg-1 intraperitoneally by a single injection to induce acute seizure. Sir 0.3, 1.0 and 3.0 mg · kg-1 was injected 24 h after seizure every other day until 3 d, 1 week, 3 weeks, 5 weeks and 6 weeks. Western blotting analysis was used to detect the expression and phos?phorylation level of S6 protein and to determine the minimum effective dose of Sir. Effect of the mini?mum effective dose of Sir on cognitive function and body growth was observed by several evaluations. Immunofluorescent intensity of Doublecortin (DCX) immunofluorescent staining was conducted to evaluate the development of neurons in the hippocampus. Morris water maze was used to assess the cognitive function. Tail suspension test, O maze and new object recognition test were used to study the anxiety-like behaviors of mice. RESULTS The result of Western blotting showed that Sir 0.3 mg · kg-1 had no significant effect on the phosphorylation of S6 protein in normal mice or KA mice, whereas 1.0 and 3.0 mg · kg- 1 could significantly inhibit the phosphorylation of S6 protein in KA mice (P<0.05). Sir 1.0 mg·kg-1 had no obvious effect on DCX-positive cells or body wass. Morris water maze showed that KA-induced seizure resulted in prolonged escape latency and swimming length (P<0.05), and a decreased crossing number of target quadrant (P<0.05). Sir 1.0 mg·kg-1 significantly reversed the deficit of cognitive function of KA-induced seizure mice (P<0.05), whereas no significant difference was found between Sir group and normal control group. Compared with normal control group, model group showed increased freezing time in tail suspension test (P<0.05), decreased migration length and reten?tion time in open arms in O maze (P<0.05), decreased retention time and touch frequency with new objects, migration length and average speed in new object recognition test (P<0.05). Sir 1.0 mg · kg-1 significantly reversed the above anxiety and depression status, whereas no significant difference was found between sirolimus group and normal control group. CONCLUSION Sir 1.0 mg · kg-1 inhibits the abnormal activation of mTOR pathway and the formation of epilepsy comorbidity in immature mice. Along with its mild side effect in development, Sir 1.0 mg · kg-1 will be an ideal dose to be used in the treatment of seizure in immature mice.